Orlistat and Victoza can both appear in searches about body weight, but they are not two versions of the same weight-management product. Orlistat is used in weight-management settings by limiting digestion and absorption of part of the fat in food. Victoza contains liraglutide, a GLP-1 receptor agonist, and its U.S. label centers on type 2 diabetes. Weight changes may occur with liraglutide therapy, but the Victoza brand should not be represented as carrying Saxenda’s obesity-treatment indication.
This is the named Victoza brand comparison. It includes an important U.S. pharmacy distinction: FDA-approved generic liraglutide injections referencing Victoza exist, but their regulatory status and labeling must be evaluated as diabetes products. Separately, Saxenda is the liraglutide brand historically marketed for weight management; that product has its own availability changes. For those questions, use orlistat versus Saxenda rather than assuming either liraglutide label applies to every injection.
OrliLab publishes independent educational content and may earn compensation from disclosed affiliate relationships. We do not dispense Victoza or orlistat, verify stock or decide whether a person should receive a prescription. This page helps differentiate product identity, labeled use, generic availability and relevant risks before contacting a licensed clinician or pharmacy.
The defining distinction is product purpose, not merely capsule versus injection. Victoza is the diabetes-labeled liraglutide brand, while orlistat products have weight-management labeling. For that reason, any headline claiming the medicines have the same indication would be misleading.
When a pharmacy mentions “liraglutide,” verify the precise product and its approval reference before assuming Victoza, Saxenda or another labeled formulation is being supplied.
| Dimension | Orlistat | Victoza |
|---|---|---|
| Ingredient | Orlistat | Liraglutide |
| Mechanism | Gastrointestinal lipase inhibition | GLP-1 receptor agonism |
| U.S. labeled role | Weight management | Type 2 diabetes management |
| Route | Oral capsules | Subcutaneous injection |
| Availability framework | OTC 60 mg or Rx 120 mg | Prescription brand; FDA-approved referencing generics |
| Context for weight change | Weight-management indication | Weight effects in a diabetes-treatment setting |
Victoza is labeled to improve glycemic control in adults and patients 10 years of age and older with type 2 diabetes. Its U.S. labeling also addresses reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. These indications differ from Saxenda’s obesity-related label and orlistat’s weight-management role.
If a reader is primarily researching obesity-labeled liraglutide, the separate Saxenda comparison is more relevant. Clinical diagnosis and approved product use matter more than a generic web listing that uses “weight loss” loosely.
The FDA approved the first generic liraglutide injection referencing Victoza on December 23, 2024, granting approval to Hikma, which announced a U.S. launch that month. Other Victoza-referencing approvals subsequently followed. These are diabetes-label generic products, not automatically interchangeable with generic liraglutide approved specifically by reference to Saxenda for weight management.
Check the reference brand, formulation, strength, packaging and actual dispensing labeler. For U.S. access to named diabetes products, the Victoza buying guide covers prescription and pharmacy checks rather than repeating them on this comparison page.
Liraglutide may affect weight in diabetes studies, but those trials are designed for specific clinical questions and populations. Comparing a Victoza outcome from a diabetes study with an orlistat obesity trial without adjustment for design, follow-up and background therapy is not valid direct evidence of comparative efficacy.
For orlistat-only findings, orlistat effectiveness evidence offers the appropriate supporting material. The purpose of this page is to keep weight-related observations distinct from the medicine’s approved diabetes indication.
Orlistat primarily influences intestinal fat absorption, so fat-containing meals and gastrointestinal tolerability are important counseling topics. Different orlistat strengths have different access requirements; the OTC product also has Drug Facts eligibility criteria.
Victoza is an injectable GLP-1 receptor agonist with a prescription dosing framework. Training with the injection device, treatment monitoring and any need for dose adjustment belong to the prescriber’s product-specific instructions. Neither product is a simple substitute for the other.
A person using Victoza may also take other glucose-lowering medicines. The care plan may need attention to hypoglycemia risk when certain therapies are combined and to outcomes unrelated to weight. Orlistat does not perform Victoza’s prescribed role in diabetes management.
Patients should not stop or switch a glucose-lowering prescription because a retail OTC option seems cheaper or more convenient. The intended indication must remain central to the conversation.
Orlistat may produce oily stools, urgency and changes in absorption of fat-soluble vitamins, and has warnings concerning interactions and oxalate-related kidney injury. Its contraindications include certain gastrointestinal conditions and pregnancy.
Victoza has its own boxed warning about thyroid C-cell tumors observed in rodents, contraindications involving medullary thyroid carcinoma or MEN2, and precautions related to pancreatitis, gallbladder disease and serious gastrointestinal symptoms. Refer to orlistat adverse-effect details for the orlistat-specific profile.
A Victoza branded pen, a generic approved with Victoza as its reference product and a Saxenda-referencing liraglutide pen represent potentially different prescription listings. FDA-approved generics do exist, but approval does not confirm current local stock; U.S. Victoza brand supply has also experienced limited availability in some reports during 2026. Ask the pharmacy to verify the intended product, reference label, actual manufacturer and available presentation.
For the orlistat side, orlistat pharmacy options explains how to identify OTC and Rx capsules at U.S. retail locations. Do not treat a general marketplace result as proof of a legitimate pharmacist-supplied product.
Insurance and cash payment decisions depend on brand identity, labeled purpose, formulary inclusion, authorized substitution and the exact product supplied. Someone searching for “generic liraglutide” should verify which approved indication and formulation the quote represents rather than assuming an automatic price or coverage advantage.
Orlistat pricing follows different OTC and prescription rules. The orlistat price guide explains those cost drivers without presenting unsupported dollar figures or retailer promotions.
This page answers the diabetes-branded Victoza question. The Saxenda page addresses obesity-label context and the announced phaseout of branded Saxenda shipments. For ingredient-level options rather than brands, liraglutide prescription access identifies the need to establish which actual U.S. product is intended.
A clinician may also compare obesity-specific alternatives if weight management, not diabetes treatment, is the true clinical objective. No published comparison page can establish personal eligibility or predict an individual outcome.
Victoza is diabetes-labeled liraglutide. Weight-related observations do not make it the same approved obesity product as Saxenda.
Yes, but they are distinct marketed products with different U.S. indications and labeling.
Yes. The FDA approved Hikma’s Victoza-referencing generic liraglutide injection in December 2024, with further approvals since then. The actual product, availability and correct prescription still need verification.
No. A generic referencing Victoza is tied to the diabetes-branded product, while a generic referencing Saxenda relates to weight-management labeling. Check the precise prescription and reference product.
No. Victoza requires a prescription, whereas Alli 60 mg is an OTC orlistat product with its own label requirements.
No. Orlistat inhibits gastrointestinal lipases; Victoza activates GLP-1 receptors.
Not reliably. Diabetes and weight-management trials may use different participants, endpoints and treatment backgrounds.
No. Orlistat has fat-associated bowel effects, vitamin and interaction concerns, and rare kidney risks. Victoza has GLP-1-specific warnings including thyroid C-cell tumors in rodents and pancreatitis concerns.
No. The pharmacist must verify the prescribed product, approved generic identity and applicable substitution rules. A Saxenda-referencing product is not an automatic replacement for a Victoza prescription.
Confirm whether the treatment goal is diabetes or weight management, identify the exact liraglutide product and ask the clinician or pharmacist about supply, substitution and monitoring before making a change.